



FOR IMMEDIATE RELEASE

Compugen to Present at JMP Securities Life Sciences Conference in New York

Holon, Israel - June 15, 2016 – Compugen Ltd. (NASDAQ: [CGEN](#)), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer, will present a corporate overview and update at the JMP Securities Life Sciences Conference in New York on Wednesday, June 22, at 3:00 p.m. ET.

A live webcast of the presentation will be available on Compugen's [website](#). A replay will be available one hour after the presentation ends and will be accessible for one month following the presentation.

About Compugen

Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at <http://www.cgen.com>.

Company contact:

Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892